Patents by Inventor James R. Gillig

James R. Gillig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis of bisindolylmaleimides
    Patent number: 5559228
    Abstract: The present invention provides an efficient process of reacting a bis-indolyl acid of the Formula (II): ##STR1## wherein R.sup.1 is a hydrogen or C.sub.1 -C.sub.4 alkyl and R, X, and Y are optional substitutions; to produce a bis-indolyloxallic acid of the Formula (III): ##STR2## Compounds of the Formula (III) are readily converted to the bis-indolylmaleimides.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: September 24, 1996
    Assignee: Eli Lilly and Company
    Inventors: James R. Gillig, Michael R. Jirousek
  • Protein kinase C inhibitors
    Patent number: 5491242
    Abstract: The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. The present invention also provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: February 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: James R. Gillig, Michael R. Jirousek
  • Protein kinase C inhibitors
    Patent number: 5481003
    Abstract: The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. The present invention also provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: January 2, 1996
    Assignee: Eli Lilly and Company
    Inventors: James R. Gillig, Michael R. Jirousek